LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

In rheumatic heart disease–associated AF, rivaroxaban increased adverse vascular outcomes vs. VKA at 3 y

Photo by ldxcreative from unsplash

SOURCE CITATION Connolly SJ, Karthikeyan G, Ntsekhe M, et al. Rivaroxaban in rheumatic heart disease-associated atrial fibrillation. N Engl J Med. 2022;387:978-88. 36036525. Click to show full abstract

SOURCE CITATION Connolly SJ, Karthikeyan G, Ntsekhe M, et al. Rivaroxaban in rheumatic heart disease-associated atrial fibrillation. N Engl J Med. 2022;387:978-88. 36036525.

Keywords: rivaroxaban; rheumatic heart; heart disease; disease associated

Journal Title: Annals of Internal Medicine
Year Published: 2023

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.